SCHEMBL23780468

SCHEMBL23780468

CC(Nc1cc(Cl)ncn1)c1ccc(Br)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRCP P42785 4/20 0.45
HTR7 P34969 3/20 0.43
EGFR P00533 6/20 0.42
HPGD P15428 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
JAK2 O60674 1/20 0.40
JAK3 P52333 1/20 0.40
MEN1 O00255 1/20 0.39
TP53 P04637 1/20 0.39
MAPT P10636 1/20 0.39
ALOX15 P16050 1/20 0.39
PPARG P37231 1/20 0.39
KMT2A Q03164 1/20 0.39
NCOA2 Q15596 1/20 0.39
NCOA1 Q15788 1/20 0.39
NCOA3 Q9Y6Q9 1/20 0.39
NPC1 O15118 1/20 0.39
PLK1 P53350 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20575148 0.85 HTR7 (0.53) PRCPHTR7EGFRJAK2JAK3
SCHEMBL20575147 0.85 HTR7 (0.53) PRCPHTR7EGFRJAK2JAK3
SCHEMBL21593091 0.84 HTR7 (0.58) PRCPHTR7EGFRJAK2JAK3
SCHEMBL4375466 0.84 HTR7 (0.58) PRCPHTR7EGFRJAK2JAK3
SCHEMBL4375461 0.84 HTR7 (0.58) PRCPHTR7EGFRJAK2JAK3
SCHEMBL28354736 0.82 HTR7 (0.43) PRCPHTR7EGFRHPGDSMN1; SMN2
SCHEMBL23291891 0.81 EGFR (0.45) PRCPHTR7EGFRJAK2JAK3
SCHEMBL23780415 0.81 PRCP (0.43) PRCPHTR7EGFRJAK2JAK3
SCHEMBL20575173 0.78 PRCP (0.42) PRCPHTR7JAK2JAK3
SCHEMBL1531644 0.75 MEN1 (0.49) PRCPHTR7SMN1; SMN2JAK2JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12187712-B2 Cardiac sarcomere inhibitors CYTOKINETICS, INC. (US) 2025-01-07 US disclosed
EP-3814343-B1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS INC (US) 2023-01-11 EP disclosed
EP-3814343-B1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS INC (US) 2023-01-11 EP disclosed
US-20210276991-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2021-09-09 US disclosed
US-20210276991-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2021-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12187712-B2 Cardiac sarcomere inhibitors TNNI3, TNNT2, MYLK2 PRCP 3219/4885HTR7 4221/4885EGFR 4830/4885
US-20210276991-A1 CARDIAC SARCOMERE INHIBITORS TNNI3, TNNT2, MYLK2 PRCP 3219/4885HTR7 4221/4885EGFR 4830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.